Balchem (NASDAQ:BCPC) Price Target Raised to $190.00 at HC Wainwright

Balchem (NASDAQ:BCPC) had its target price hoisted by HC Wainwright from $185.00 to $190.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the basic materials company’s stock.

Separately, StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th.

Balchem Stock Performance

BCPC opened at $172.51 on Monday. The stock has a market capitalization of $5.61 billion, a price-to-earnings ratio of 46.37, a PEG ratio of 5.12 and a beta of 0.65. Balchem has a fifty-two week low of $116.84 and a fifty-two week high of $186.03. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98. The company has a fifty day moving average of $171.70 and a 200 day moving average of $163.41.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Los Angeles Capital Management LLC raised its stake in Balchem by 33.1% during the third quarter. Los Angeles Capital Management LLC now owns 4,588 shares of the basic materials company’s stock valued at $807,000 after purchasing an additional 1,140 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in shares of Balchem by 20.5% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 3,034 shares of the basic materials company’s stock worth $534,000 after buying an additional 517 shares during the last quarter. Legacy Capital Wealth Partners LLC purchased a new stake in shares of Balchem during the 3rd quarter valued at about $232,000. Atria Investments Inc lifted its holdings in shares of Balchem by 8.5% in the 3rd quarter. Atria Investments Inc now owns 2,708 shares of the basic materials company’s stock valued at $477,000 after acquiring an additional 212 shares during the last quarter. Finally, Fiera Capital Corp bought a new position in shares of Balchem in the 3rd quarter valued at about $4,201,000. 87.91% of the stock is owned by hedge funds and other institutional investors.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.